Emergent Biosolutions Price to Sales Ratio 2010-2022 | EBS

Historical PS ratio values for Emergent Biosolutions (EBS) over the last 10 years. The current P/S ratio for Emergent Biosolutions as of May 27, 2022 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Emergent Biosolutions P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2022-05-27 35.22 1.07
2022-03-31 41.06 $32.92 1.25
2021-12-31 43.47 $33.15 1.31
2021-09-30 50.07 $30.62 1.64
2021-06-30 62.99 $31.59 1.99
2021-03-31 92.91 $31.60 2.94
2020-12-31 89.60 $29.01 3.09
2020-09-30 103.33 $25.05 4.12
2020-06-30 79.08 $23.92 3.31
2020-03-31 57.86 $21.26 2.72
2019-12-31 53.95 $21.28 2.53
2019-09-30 52.28 $19.68 2.66
2019-06-30 48.31 $17.08 2.83
2019-03-31 50.52 $16.66 3.03
2018-12-31 59.28 $15.32 3.87
2018-09-30 65.83 $13.90 4.74
2018-06-30 50.49 $13.49 3.74
2018-03-31 52.65 $11.20 4.70
2017-12-31 46.47 $11.18 4.16
2017-09-30 40.45 $10.40 3.89
2017-06-30 33.91 $10.33 3.28
2017-03-31 29.04 $10.59 2.74
2016-12-31 32.84 $10.37 3.17
2016-09-30 31.53 $10.28 3.07
2016-06-30 26.35 $10.70 2.46
2016-03-31 34.06 $11.09 3.07
2015-12-31 37.49 $10.64 3.52
2015-09-30 26.70 $9.88 2.70
2015-06-30 30.88 $9.53 3.24
2015-03-31 26.95 $9.75 2.76
2014-12-31 25.52 $9.54 2.68
2014-09-30 19.97 $9.97 2.00
2014-06-30 21.05 $9.42 2.23
2014-03-31 23.68 $8.80 2.69
2013-12-31 21.54 $8.53 2.52
2013-09-30 17.85 $8.46 2.11
2013-06-30 13.51 $7.87 1.72
2013-03-31 13.10 $7.54 1.74
2012-12-31 15.03 $7.73 1.94
2012-09-30 13.32 $8.12 1.64
2012-06-30 14.20 $7.91 1.79
2012-03-31 14.99 $8.39 1.79
2011-12-31 15.78 $7.52 2.10
2011-09-30 14.46 $7.72 1.87
2011-06-30 21.13 $8.41 2.51
2011-03-31 22.64 $7.95 2.85
2010-12-31 21.98 $8.91 2.47
2010-09-30 16.17 $7.46 2.17
2010-06-30 15.31 $6.52 2.35
2010-03-31 15.73 $6.94 2.27
2009-12-31 12.73 $7.50 1.70
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.770B $1.793B
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00